svgIcon
2013 Founded
svgIcon
12,000+ Employees
svgIcon
Unknown Revenue
svgIcon
$200 and More Avg. Salary

Linked Accounts

About Company

Elucid is a Boston-based medical technology company specializing in AI-powered imaging analysis software for cardiovascular disease assessment. Their flagship product, PlaqueIQâ„¢, is the first and only non-invasive software validated against histopathology to quantify arterial plaque characteristics, including lipid-rich necrotic core, calcification, and intraplaque hemorrhage. This technology enables physicians to make more precise, personalized treatment decisions for patients with known or suspected cardiovascular disease .

Company Overview

  • Founded: 2013

  • Headquarters: 399 Boylston Street, Suite 400, Boston, MA 02116, USA

  • Alternate Address: 225 Main Street, Suite 15, Wenham, MA 01984, USA

  • Phone: +1-617-329-9487

  • Email: info@elucid.com

  • Website: elucid.com

Leadership Team

  • Kelly Huang, PhD – President & CEO

  • Blake Richards – Chief Operating Officer

  • Andrew Miller – Chief Technology Officer & SVP, Engineering

  • Windi Hary – Chief Regulatory & Quality Officer

  • Sophie Khem – SVP, Clinical Quality & Delivery

  • Amy Kruglak – SVP, People & Leadership Development

  • Kevin Mathews – SVP, Marketing

  • Amir Ahmadi, MD – Chief Scientific Advisor

Recent Developments

  • In November 2023, Elucid raised $80 million in a Series C funding round led by Elevage Medical Technologies to accelerate the commercialization of its AI-powered diagnostic tools .

  • The company received FDA 510(k) clearance for its PlaqueIQâ„¢ image analysis software in October 2024, marking it as the first software validated on ground-truth histology for plaque characterization .

  • Elucid has expanded its leadership team and moved into new headquarters in Boston to support its growth and the upcoming commercial launch of PlaqueIQâ„¢

Be a First Reviewer

Leave a review